ZymoGenetics: Clinical Trials

5 trials sponsored by ZymoGenetics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 1, Unknown 1
Phase 11Completed 1
Phase 31Terminated 1

Follow ZymoGenetics: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
PEG-rIL-29, Peginterferon alfa-2a, Ribavirin - Hepatitis C, Chronic
Phase 2UnknownZymoGenetics6002010-05-012011-12-05
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
recombinant human interleukin-21, immunohistochemistry staining method, laboratory biomarker analysis - Melanoma (Skin)
Phase 2CompletedNCIC Clinical Trials Group402007-12-132023-08-04
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
Atacicept, Mycophenolate mofetil, Placebo - Lupus Nephritis
Phase 2 / Phase 3TerminatedEMD Serono62007-12-012016-03-23
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
rIL-21 only, rIL-21 + sorafenib - Carcinoma, Renal Cell
Phase 1 / Phase 2CompletedZymoGenetics522006-10-012009-05-27
Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting
rThrombin - Surgical Hemostasis
Phase 2CompletedZymoGenetics722006-08-012009-03-09

Conditions studied

Carcinoma, Renal Cell (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Infections (1)  ·  Liver Diseases (1)  ·  Lupus Nephritis (1)  ·  Melanoma (1)  ·  Nephritis (1)  ·  Virus Diseases (1)

Interventions

Adrenal Cortex Hormones (1)  ·  Immunohistochemistry (1)  ·  Mycophenolic Acid (1)  ·  Ribavirin (1)  ·  Sorafenib (1)  ·  TACI receptor-IgG Fc fragment fusion protein (1)  ·  peginterferon alfa-2a (1)  ·  peginterferon lambda-1a (1)  ·  recombinant human thrombin (1)

Countries

United States (4)  ·  Canada (2)  ·  Australia (1)  ·  Austria (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  Romania (1)  ·  Singapore (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Allan Alexander, MD (1)  ·  Jan Hillson, MD (1)  ·  Naomi Hunder, MD (1)  ·  Teresa M. Petrella (1)

Results publications

PMID 22325903, PMID 22915661, PMID 24829759, PMID 25042797, PMID 25043197

NIH funding

2009 (1)